在电疗法期间使用类似葡萄糖-1受体激活剂:病例报告与不断变化的担忧和管理考虑
Randall T Espinoza1, Zarah Antongiorgi2
1From the Department of Psychiatry and Biobehavioral Sciences.
The journal of ECT
|February 5, 2024
概括
用于糖尿病和肥胖症的葡萄糖类-1受体激动剂可能会增加麻醉期间吸入风险. 本案例报告讨论了在电疗法 (ECT) 期间管理这些风险.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 麻醉学 麻醉学
- 神经学 神经学
背景情况:
- 类似葡萄糖-1受体激动剂 (GLP-1RA) 正在彻底改变糖尿病和肥胖管理.
- GLP-1RA与延迟胃排空有关,可能在麻醉期间增加吐和吸收风险.
- 现有的指导方针针对一般麻醉的这些风险,但不专门针对电疗法 (ECT).
更多相关视频
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
12.1K
04:29Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
28.6K
相关概念视频
Electroconvulsive Therapy
41
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
41
Glucagon-like Receptor Agonists
323
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
323
